Significant impact of promoter hypermethylation and the 540 C>T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase

American Journal of Pathology

Volumn 161, Issue 1, 2002, Pages 229-237

  Straume, OddbjØrn ^a   Smeds, J ^b   Kumar, R ^b   Hemminki, K ^b   Akslen, Lars Andreas ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DNA POLYMORPHISM; GENE MUTATION; GROWTH CURVE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MELANOMA; METHYLATION; POINT MUTATION; PRIORITY JOURNAL; TUMOR CELL; TUMOR GROWTH;

EID: 0036313607     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64174-0     Document Type: Article

References (52)

1. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4
2. A novel p16INK4A transcript
3. A cell cycle regulator potentially involved in genesis of many tumor types
4. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers
5. Role of the p16 tumor suppressor gene in cancer
6. The genetics of hereditary melanoma and nevi. 1998 update
7. Germline p16 mutations in familial melanoma
8. Genetic basis of susceptibility to melanoma
9. p16(MTS-1/CDKN2/INK4a) in cancer progression
10. Mutations in the CDKN2A (p16INK4a) gene in microdissected sporadic primary melanomas
11. Hypermethylation of tumor suppressor genes in cancer
12. Methylation of the 5′ CpG island of the p16/ CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing
13. p16INK4a inactivation is not frequent in uncultured sporadic primary cutaneous melanoma
14. Low frequency of p16/ CDKN2A methylation in sporadic melanoma: Comparative approaches for methylation analysis of primary tumors
15. p16INK4a expression is frequently decreased and associated with 9p21 loss of heterozygosity in sporadic melanoma
16. Analysis of the tumor suppressor gene p16(INK4A) in microdissected melanoma metastases by sequencing, and microsatellite and methylation screening
17. Deletion mapping of chromosome region 9p21-p22 surrounding the CDKN2 locus in melanoma
18. Loss of heterozygosity in sporadic primary cutaneous melanoma
19. Loss of heterozygosity at chromosome 9p21 (INK4-p14ARF locus): Homozygous deletions and mutations in the p16 and p14ARF genes in sporadic primary melanomas
20. A single nucleotide polymorphism in the 3′ untranslated region of the CDKN2A gene is common in sporadic primary melanomas but mutations in the CDKN2B, CDKN2C, CDK4 and p53 genes are rare
21. Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma
22. Reduced survival in patients with ductal pancreatic adenocarcinoma associated with CDKN2 mutation
23. Altered p16/MTS1/CDKN2 and cyclin D1/PRAD-1 gene expression is associated with the prognosis of squamous cell carcinoma of the esophagus
24. p16 inactivation in small-sized lung adenocarcinoma: Its association with poor prognosis
25. Deletions of p15 and/or p16 genes as a poor-prognosis factor in adult T-cell leukemia
26. Melanocytic tumors of the skin
27. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma
28. The histogenesis and biologic behavior of primary human malignant melanomas of the skin
29. Correlation of Ki-67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel "paraffin"-reactive MIB1 antibody [see comments]
30. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands
31. In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis
32. Regression models and life-tables
33. The p16INK4a/CDKN2A tumor suppressor and its relatives
34. Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice
35. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis
36. Promoter hypermethylation: A common cause of reduced p16(INK4a) expression in uveal melanoma
37. Lack of mutation at p16INK4A gene but expression of aberrant p16INK4A RNA transcripts in human ovarian carcinoma
38. Inactivation of p16 in human mammary epithelial cells by CpG island methylation
39. p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer
40. K-ras and p16 aberrations confer poor prognosis in human colorectal cancer
41. Hypermethylation of the p16 gene in sporadic T3NOMO stage colorectal cancers: Association with DNA replication error and shorter survival
42. Distinct patterns of inactivation of p151NK4B and p16INK4A characterize the major types of hematological malignancies
43. Aberrant p27Kip1 promoter methylation in malignant melanoma
44. Disruption of the RB pathway and cell-proliferative activity in non-small-cell lung cancers
45. Aberrant promoter methylation of multiple genes in nonsmall cell lung cancers
46. Loss of p16 protein expression associated with methylation of the p16INK4A gene is a frequent finding in Hodgkin's disease
47. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma
48. Infrequent mutation of p16INK4 in sporadic melanoma
49. p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression
50. The 3′ untranslated region of messenger RNA: A molecular 'hotspot' for pathology?
51. Analysis of G(1)/S checkpoint regulators in metastatic melanoma